Endocannabinoid Enzymes play a central biochemical role in regulating how the human body synthesises, transports, and breaks down endogenous lipid messengers. While much public discussion around hemp science centres on plant-derived compounds such as cannabidiol (CBD) and cannabinoid receptors, researchers increasingly examine the metabolic enzymes that control the lifespan of endocannabinoids within the body. Understanding how these specialised proteins operate provides essential foundational knowledge for anyone exploring modern cannabinoid biochemistry and broad-spectrum hemp science in Australia.
In this educational guide, we examine the primary metabolic proteins responsible for endocannabinoid synthesis and degradation, how they interact with phytocannabinoids in laboratory research, and five vital biochemical facts that define this fascinating field of study.

What Are Endocannabinoid Enzymes?
Within the human endocannabinoid system (ECS), chemical signalling relies on three core components: endogenous lipid ligands (primarily anandamide and 2-arachidonoylglycerol), G-protein-coupled cannabinoid receptors (CB1 and CB2), and the specialised proteins that manufacture and dismantle those ligands on demand. Unlike classical neurotransmitters such as serotonin or dopamine, which are stored in synaptic vesicles ahead of time, endocannabinoids are synthesised immediately from cell membrane phospholipids when needed and rapidly broken down once their signalling role concludes.
Endocannabinoid Enzymes act as the metabolic gatekeepers of this system. Biosynthetic enzymes assemble endocannabinoids from fatty acid precursors, while catabolic (hydrolytic) enzymes cleave those molecules back into inactive components. By tightly regulating local concentrations of anandamide (AEA) and 2-arachidonoylglycerol (2-AG), these enzymes maintain biochemical balance across neural and peripheral tissues.
5 Vital Facts About Endocannabinoid Enzymes
1. FAAH Is the Primary Enzyme Responsible for Breaking Down Anandamide
Fatty acid amide hydrolase (FAAH) is an intracellular membrane-bound serine hydrolase that serves as the principal catabolic enzyme for anandamide, often referred to as the “bliss molecule” after the Sanskrit word ananda. Once anandamide completes its interaction with cannabinoid receptors, FAAH hydrolyses the molecule into arachidonic acid and ethanolamine. In biochemical literature, FAAH activity is recognised as the primary rate-limiting factor determining how long anandamide remains active in extracellular spaces.
2. MAGL Regulates the Breakdown of 2-Arachidonoylglycerol (2-AG)
While FAAH targets anandamide, monoacylglycerol lipase (MAGL) is responsible for approximately 85 percent of the hydrolysis of 2-arachidonoylglycerol (2-AG) in the central nervous system. MAGL converts 2-AG into free arachidonic acid and glycerol. Additional serine hydrolases, specifically ABHD6 and ABHD12, account for the remaining portion of 2-AG degradation, illustrating the multi-layered precision built into human lipid metabolism.
3. Biosynthetic Enzymes Produce Endocannabinoids On Demand
Before degradation can occur, distinct biosynthetic enzymes must construct endocannabinoids directly from lipid precursors embedded in cellular membranes:
- NAPE-PLD (N-acyl phosphatidylethanolamine-specific phospholipase D): Catalyses the primary pathway that generates anandamide from membrane phospholipids in response to calcium influx.
- DAGL-alpha and DAGL-beta (Diacylglycerol lipases): Cleave diacylglycerol precursors to produce 2-AG on demand within postsynaptic neurons and peripheral cells.
4. Phytocannabinoids Interact With Metabolic Pathways in Preclinical Studies
Laboratory and pharmacological studies have investigated how plant-derived cannabinoids from Cannabis sativa interact with these metabolic proteins. Unlike tetrahydrocannabinol (THC), which binds directly as a partial agonist to CB1 receptors, cannabidiol (CBD) exhibits very low direct binding affinity for CB1 and CB2 receptors. Instead, preclinical biochemical research indicates that CBD can interact with fatty acid-binding proteins (FABPs) that transport anandamide intracellularly to FAAH, as well as modulate certain cytochrome P450 (CYP450) liver enzymes involved in general compound metabolism.
5. Genetic Variations in FAAH Influence Baseline Enzyme Activity
Human genetic research has identified naturally occurring single-nucleotide polymorphisms (SNPs) within the gene encoding FAAH—most notably the C385A variant. Individuals carrying this genetic variation produce a version of the FAAH enzyme that is more susceptible to cellular degradation, resulting in lower baseline FAAH activity and measurably higher circulating levels of anandamide. These findings highlight how individual biochemistry varies naturally across human populations.
Key Metabolic Enzymes at a Glance
| Enzyme Name | Primary Function | Target Endocannabinoid | Primary Breakdown Products |
|---|---|---|---|
| FAAH | Catabolic (Hydrolysis) | Anandamide (AEA) | Arachidonic acid & ethanolamine |
| MAGL | Catabolic (Hydrolysis) | 2-Arachidonoylglycerol (2-AG) | Arachidonic acid & glycerol |
| NAPE-PLD | Biosynthetic (Synthesis) | Produces Anandamide (AEA) | Synthesised from NAPE lipids |
| DAGL-α / DAGL-β | Biosynthetic (Synthesis) | Produces 2-AG | Synthesised from diacylglycerol |
Australian Regulatory Standards and Quality Assurance
In Australia, medicinal cannabis and cannabidiol products are strictly regulated at the federal level to ensure consumer safety, accurate cannabinoid composition, and freedom from contaminants. The Therapeutic Goods Administration (TGA) oversees product quality standards, scheduling rules, and manufacturing compliance across the Australian market.
For readers looking to understand how hemp extracts are formulated, tested, and verified for cannabinoid purity, you can explore additional educational resources on our Purest CBD Australia blog or browse our CBD Education archive, where we break down laboratory testing certificates, extraction methodologies, and hemp plant chemistry.
Recent Comments